sheila RHEUMarampa
4 years ago
ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph 3 trial. @RheumNow #ACR20 abs0995 #ACRbest https://t.co/aJyASaAMlJ
Eric Dein ejdein1
4 years ago
Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk
Dr. Rachel Tate uptoTate
4 years ago
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
Mrinalini Dey DrMiniDey
4 years ago
#HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE:
- 132 patients, 108 on HCQ
- Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways
- HCQ may improve vascular health in SLE
Abs#0870 #ACR20 @RheumNow
https://t.co/ST9n2HGyhM
Dr. Rachel Tate uptoTate
4 years ago
CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC
sheila RHEUMarampa
4 years ago
In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Important to tailor our approach based on patient preferences, and this abstract shows that geriatric patients have different desires for care! #ACR20 @RheumNow https://t.co/pY3VTeURSS
Janet Pope Janetbirdope
4 years ago
Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP
sheila RHEUMarampa
4 years ago
SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9
sheila RHEUMarampa
4 years ago
Anti-PAD Abs seen in 1/3 of pts at-risk for RA and 1/3 of pts w/ CSA.
Implications? Possible predictive value of anti-PAD Abs in RA dse progression?
@RheumNow #ACR20 abs0761 #ACRbest https://t.co/VpkjwU2YZm
Mrinalini Dey DrMiniDey
4 years ago
Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug.
#RheumTwitter #lupus
Abs#0849 #ACR20 @RheumNow
https://t.co/8a6OcZmOso
alexa meara lexmeara
4 years ago
The development of biologics started with diphtheria- history of Medicine! Look how far we have come now prescribing over 50 different types of biologics! @RheumNow #acr20 https://t.co/XbygK5g7ON
Dr. Rachel Tate uptoTate
4 years ago
BKZ tx improved BASDAI total and single question scores related to fatigue and neck, back and hip pain in pts with PsA. #ABS0906 #ACR20 @RheumNow https://t.co/GzpJfkwvL5 https://t.co/KnJAqAKlqq
Janet Pope Janetbirdope
4 years ago
Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs
Mrinalini Dey DrMiniDey
4 years ago
Valerio et al find 40% of 294 patients w/ #rheumaticdisease refuse or are uncertain about getting inactivated #influenza #vaccine. Key determinants of #vaccinehesitancy found to be concerns about adverse events, safety & efficacy.
Abs#0632 #ACR20 @RheumNow
https://t.co/f34DAc5WiN